PCNA and neoplasm: Concordantly, while sunitinib treatment could effectively inhibit tumor growth in the control groups, the PCIF1 knockdown group exhibited a superior response to treatment reflected in tumor weight and size (Figure 7C–E), accompanied by a significantly decreased staining of PCNA and angiogenesis marker CD31 (Figure 7F).